Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.
Malhotra J, Chiappori A, Fujioka N, Hanna NH, Feldman LE, Patel M, Moore D, Chen C, Jabbour SK. Malhotra J, et al. Among authors: chiappori a. Lung Cancer. 2024 Sep;195:107932. doi: 10.1016/j.lungcan.2024.107932. Epub 2024 Aug 21. Lung Cancer. 2024. PMID: 39173229 Clinical Trial.
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
Chen L, Kurtyka CA, Welsh EA, Rivera JI, Engel BE, Muñoz-Antonia T, Yoder SJ, Eschrich SA, Creelan BC, Chiappori AA, Gray JE, Ramirez JL, Rosell R, Schabath MB, Haura EB, Chen DT, Cress WD. Chen L, et al. Among authors: chiappori aa. Oncotarget. 2016 Dec 13;7(50):82254-82265. doi: 10.18632/oncotarget.12672. Oncotarget. 2016. PMID: 27756884 Free PMC article. Clinical Trial.
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.
Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. Saltos AN, et al. Among authors: chiappori aa. Lung Cancer. 2023 Sep;183:107313. doi: 10.1016/j.lungcan.2023.107313. Epub 2023 Jul 22. Lung Cancer. 2023. PMID: 37499521 Clinical Trial.
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Chiappori AA, et al. Clin Cancer Res. 2008 Mar 1;14(5):1464-9. doi: 10.1158/1078-0432.CCR-07-1508. Clin Cancer Res. 2008. PMID: 18316570 Clinical Trial.
119 results